XML 34 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Balance Sheet Components (Tables)
9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Cash Equivalents and Available-for-sale Securities
Cash equivalents and available-for-sale securities consisted of the following (in thousands):
 
September 30, 2017
 
Amortized
Cost
 
Gross Unrealized
 
 
 
Gains
 
Losses
 
Fair Value
Money market funds
$
47,638

 
$

 
$

 
$
47,638

Corporate bonds
7,502

 

 
(7
)
 
7,495

Government bonds
47,056

 

 
(44
)
 
47,012

Total cash equivalents and available-for-sale securities
$
102,196

 
$

 
$
(51
)
 
$
102,145

Classified as:
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
 
 
$
47,638

Available-for-sale securities - current
 
 
 
 
 
 
43,191

Available-for-sale securities - noncurrent
 
 
 
 
 
 
11,316

Total cash equivalents and available-for-sale securities
 
 
 
 
 
 
$
102,145


 
December 31, 2016
 
Amortized
Cost
 
Gross Unrealized
 
 
 
Gains
 
Losses
 
Fair Value
Money market funds
$
11,270

 
$

 
$

 
$
11,270

Corporate bonds
21,886

 

 
(45
)
 
21,841

Commercial paper
10,769

 

 

 
10,769

Government bonds
41,316

 
2

 
(29
)
 
41,289

Total cash equivalents and available-for-sale securities
$
85,241

 
$
2

 
$
(74
)
 
$
85,169

Classified as:
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
 
 
$
18,504

Available-for-sale securities - current
 
 
 
 
 
 
56,515

Available-for-sale securities - noncurrent
 
 
 
 
 
 
10,150

Total cash equivalents and available-for-sale securities
 
 
 
 
 
 
$
85,169

Summary of Accrued Expenses and Other Payables
Accrued expenses and other payables consisted of the following (in thousands):
 
September 30, 2017
 
December 31, 2016
Accrued clinical and research related expenses
$
5,864

 
$
3,617

Accrued employee related expenses
1,611

 
1,420

Accrued professional service fees
709

 
115

Other
57

 
120

Total accrued expenses and other payables
$
8,241

 
$
5,272